|
Oxford BioMedica plc - Company Profile Snapshot
| Company Profile: |
Oxford BioMedica plc |
| Ticker: |
OXB |
| Exchanges: |
LON |
| 2008 Sales: |
18,394,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED KINGDOM |
| Employees: |
85 |
Business Description
Oxford BioMedica plc. The Group's principal activity is researching and developing genebased medicines and therapeutic vaccines based on a broad technology platform. The Group's development pipeline comprises four products in clinical development and a late-stage preclinical candidate. The lead product is TroVax,a therapeutic vaccine that has potential application in a range of tumour types. The product is designed to stimulate a specific anti-cancer immune response against a protein called 5T4. The Group's other products are Hi-8 MEL, MetXia, ProSavin and RetinoStat. The Group operates in the United Kingdom and the United States of America.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
